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Abstract 5 
In a prospective single-center longitudinal randomized controlled trial 116 patients were 6 
allocated to the sub-vastus approach, and 115 to the medial parapatellar approach.  At one 7 
week follow-up, compared to baseline, range of motion, Knee Society (KS) global, KS 8 
knee, and KS pain scores were significantly better in the sub-vastus group.  At the one year 9 
follow-up WOMAC global and pain scores, SF36 physical function and role-physical 10 
scores, and EuroQol utility and pain score were significantly better in the sub-vastus 11 
group. The ease of exposure in the sub-vastus approach was significantly worse. There 12 
was no significant difference in length of stay or analgesia intake. The sub-vastus approach 13 
to total knee arthroplasty was more effective than a medial parapatellar approach at both 14 
one week and fifty-two weeks post-operatively, but surgeons reported a less easy exposure 15 
in the sub-vastus group.  16 
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Introduction 25 
Knee arthritis is a common disabling problem and when advanced and following failure of 26 
conservative measures total knee arthroplasty is a recommended option [1,2]. In small 27 
randomized controlled trials patients who received a sub-vastus approach were reported to 28 
have better short-term functional outcomes than those treated with the traditional medial 29 
parapatellar approach [3,4,5,6]. The issue of best choice of surgical approach remains 30 
controversial [7].  In one survey, the medial parapatellar approach was reported to be used 31 
for the vast majority of total knee replacements [8].  Each approach has potential 32 
advantages and drawbacks, and to our knowledge there has been no reasonably sized 33 
comparison of the two approaches with a one-year follow-up. 34 
 35 
We performed a single-center longitudinal, prospective, randomized controlled trial to 36 
compare the sub-vastus approach (the “intervention” group) to total knee arthroplasty with 37 
the medial parapatellar approach (the “control” group).  We wished to determine the 38 
impact of these choices of sub-vastus or medial parapatellar approach on functional and 39 
clinical outcomes, up to one year after surgery.  40 
 41 
42 
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Materials and Methods 43 
Setting and Locations  44 
The trial was approved by the local Ethics and Scientific Merit Committees.  Seven 45 
accredited consultant surgeons in one English orthopaedic university-affiliated teaching 46 
hospital participated.  Surgeons mainly consulted and operated at this hospital, but they 47 
also operated at another English university-affiliated teaching hospital forty miles from the 48 
main hospital, and at a local private hospital. Recruitment began in February 2001, and the 49 
last participant was recruited in August 2003.   A Trial Steering Group chaired by a senior 50 
clinical researcher from another institution met on a six-monthly basis. An independent 51 
Data Monitoring Committee was chaired by a senior medical statistician who had no other 52 
involvement in this study. The decision to discontinue was only to be made if the results 53 
were likely to be convincing to our clinicians, participants in the trial and the general 54 
clinical community. A nominal significance level for stopping the trial was p<= 0.02 [9]. 55 
Eligibility Criteria 56 
Eligible patients were those awaiting a primary unilateral total knee arthroplasty for any 57 
indication, who had not had or were not planned to have a major arthrotomy in the other 58 
knee within 12 months, who had not had previous open surgery in or around the knee in 59 
the previous 12 months, (e.g. high tibial osteotomy, femoral osteotomy, fracture fixation, 60 
patellar realignment, patellectomy and open meniscectomy), who had a valgus angle of < 61 
20, and who had a surgeon who had no clear preference for either surgical approach.  62 
 Randomization 63 
At the start of the trial, participating surgeons elected to randomize patients to be treated 64 
with either one of two approaches, the sub-vastus approach, or medial parapatellar 65 
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approach. Entry of a patient into the trial and treatment allocation were accomplished 66 
through a remote computer-based telephone service.  The operating consultant surgeon 67 
telephoned the trials office to have the patient allocated to an approach, when their patient 68 
was escorted to the anaesthetic room immediately prior to surgery.  Patients were 69 
allocated with minimisation on surgeon and gender [10].  70 
Details of the Interventions  71 
The two randomly allocated treatments were a medial parapatellar approach [11] and a 72 
sub-vastus approach [12]  for total knee arthroplasty.  The operating consultant surgeon 73 
responsible for the care of each patient ensured that all procedures were performed by 74 
surgeons who were competent to undertake the allocated procedure, and performed or 75 
directly supervised all operations.  The Low Contact Stress (LCS®, Depuy) Mobile-76 
Bearing Total  Knee prosthesis was used in all procedures. Subsequent management 77 
followed the consultant orthopaedic surgeon’s standard care pathway and practice, 78 
including if necessary the management of any complications.  79 
Data Collection 80 
Data were collected at five main time-points, on hospital admission prior to surgery, in 81 
hospital one-week post-operatively or at home if already discharged, and in the clinic at six 82 
weeks, 12 weeks, and one year following surgery.    A blinded trained research 83 
physiotherapist or physiotherapy assistant recorded clinical measurements.  The operating 84 
surgeon, who otherwise had no role in collecting or analyzing data, recorded surgical 85 
details and peri-operative measures.  Questionnaires were given to patients, explained, and 86 
collected by a research nurse (GW).  The nurse (GW) or research assistant (DC) ensured 87 
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data completeness.   The nurse collected other clinical data from case-notes.  Participants 88 
were blinded to approach. 89 
Outcomes 90 
The primary outcome measure for this study was change in Knee Society Score [13] at one 91 
year compared to baseline, with this measure a secondary outcome at other time-points 1, 92 
6 and 12 weeks post-operatively. The Knee Society Clinical Rating System, is composed 93 
of a knee score and a functional score.  The knee score is made up from components of 94 
pain, stability and range of motion, with deductions for flexion contracture, extension lag 95 
and malalignment.  The pain component is measured on a 7 point scale from 0 points 96 
(severe) to 50 points (none). The functional score considers walking distance and stair 97 
climbing, with deductions for walking aids.  Both the knee and functional scores range 98 
from 0 (worst) to 100 (best).   99 
The Western Ontario McMaster Osteoarthritis Index (WOMAC) [14], is a 24-item arthritis 100 
and lower limb specific measure of pain (5 questions), stiffness (2 questions) and physical 101 
functional difficulty (17 questions).  It is available in two formats, visual analogue and 102 
Likert scales with similar metric properties [15].  We used the format with 5 Likert-boxes 103 
per item.  We calculated a summary score for each dimension, with maximum scores of 20, 104 
8 and 68 for the Likert version [14], with lower scores better.   Its reliability, validity and 105 
responsiveness are well-established [16].  The pain component of the WOMAC ranges 106 
from 0 no pain on any question, to 20, extreme pain on each question. 107 
 108 
The Medical Outcomes Study Short Form 36 (SF36) [17] is a self-completion 109 
questionnaire consisting of 36 items across eight components; physical function (10 items); 110 
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role limitation due to physical problems (4 items); bodily pain (2 items); general health (5 111 
items);  role limitation due to emotional problems (3 items); social function (2 items); 112 
mental health (5 items); energy/vitality (4 items). It is usually used to provide an eight-item 113 
profile of scores across the range of health domains, although physical and mental 114 
summary scores combining the first four, and last four items can also be used [18]. It is a 115 
generic measure, as opposed to one that targets a specific age, disease, or treatment group.  116 
All scales were transformed to score between 0 (worst) and 100 (best). 117 
The EuroQol [19] is a general measure of self-reported current health related quality of life 118 
that has been designed to complement other quality of life and disease specific measures 119 
[20].  It measures five dimensions of mobility, self-care, usual activities, pain/discomfort, 120 
and anxiety/depression, on three level scales (no symptoms or problems, moderate 121 
symptoms or some problems, and extreme symptoms or total inability), scored zero, one or 122 
two respectively.  The descriptive data is used to generate a weighted health index, based 123 
on tables of values derived from general population samples.  The EuroQol also provides a 124 
patient rated health status on a visual analogue scale from 0, worst imaginable health state, 125 
to 100, best imaginable health state.    126 
Further outcome measures included; daily patient reported knee pain during the first  post-127 
operative week, measured on a  visual analogue scale, from  0 (no pain) to 10 (worst 128 
possible pain); use of analgesia during the first post-operative week, from prescription 129 
charts;  complications as recorded in medical records and as reported by patients at their 130 
research follow-up appointments; length of stay in hospital (days); surgeons ease of 131 
exposure  measured with a Visual Analogue Score (VAS) ranging from 0 (easy) to 10 132 
(extremely difficult), and proportion of patients who had a lateral release. 133 
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Sample size  134 
In a group of 86 patients undergoing total knee arthroplasty the mean one-year post-135 
operative Knee Society Score was 172.2 with a standard deviation of 20 and a range of 136 
98-200 [21].  To detect a 5% increase in the post-operative Knee Society Score in the sub-137 
vastus group compared to the medial parapatellar group with a two-sided significance level 138 
of 5% and a power of 90% a sample size of 105 patients was required in each group. An 139 
additional 10% were recruited to each group to allow for any patients lost to follow-up, 140 
giving a total sample size of 231.  141 
Statistical Methods 142 
Time was measured from baseline assessment of the outcomes which were usually made 143 
on the day before or day of surgery.  Outcome variables were measured as differences 144 
(follow-up – baseline) at each time point, giving 4 differences (longitudinal repeated 145 
measures) for each patient. For example, the Womac outcome measures at weeks 1, 6, 12 146 
and 52, were computed as:  147 
                                    d1  = Womac01-Womac0 (baseline)  148 
    d6  = Womac06-Womac0 (baseline) 149 
        d12= Womac12-Womac0 (baseline) 150 
d52= Womac52-Womac0 (baseline) 151 
An advantage of this method is that plots quickly reveal the underlying trends (between 152 
groups) with time. The plot will be flat if there is no change with time, while in/decreasing 153 
trends will reveal effects positive or negative depending on the definition of the original 154 
scores. The outcome variables in the two groups were compared using t-tests, non-155 
parametric methods and the multiple logistic function using the SPSS software 156 
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package. The latter technique takes the correlation between the repeated measures 157 
into account by regarding the analysis as a comparison between the two treatment 158 
groups using the four repeated outcome measurements (d1, d6, d13 and d52). More 159 
detailed adjusted analyses were also conducted using a linear mixed model approach 160 
[30] which took into account: (a) previously selected baseline factors, (b) the trend 161 
over time (c) the correlation between the repeated measures, and (d) random error. 162 
These latter analyses were carried out using the S-Plus software package. Non-163 
parametric trend lines were computed to show the average evolution in the 164 
difference from baseline in each treatment group   165 
 166 
The primary analysis was by intention to treat, and involved all patients who were 167 
randomly assigned. The trial protocol has been described in more detail elsewhere [22]. 168 
169 
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Results 170 
(a)   Data Acquisition 171 
Patient recruitment and follow-up is summarised in a flow-diagram (Fig 1).  Two hundred 172 
and thirty-one patients were enrolled in the study, 116 were randomized to the sub-vastus 173 
(SV) approach, and 115 were randomized to the medial parapatellar (MP) approach. 174 
Twenty-three eligible patients declined to participate.  175 
In four (3.5%) patients allocated the SV approach, the MP approach was performed. In 176 
three patients, a SV approach was attempted but the operation was completed through an 177 
MP approach; in one patient the surgeon stated the shape of the leg was a problem; in a 178 
second patient the approach was deemed too difficult; and in a third the leg was too bulky.  179 
In one patient, the surgeon carried out an MP instead of SV approach by mistake. 180 
In the MP group 17/575 (3.0%) planned assessments (one at one, six at six, six at 12, and 181 
four at one year) were missed in 14 patients; in two instances because a patient elected not 182 
to have two interim assessments, in three because of death, in two illness, and in 10 for 183 
unknown reasons. In the SV Group 20/580  (3.1%) planned assessments  (four at one, six 184 
at six, seven at 12, and three at one year) were missed in 12 patients; in seven instances 185 
because of death, in two illness, in two early hospital discharge, in one a long patient 186 
holiday, in one relocation, and seven for unknown reasons.  In addition, 50 assessments 187 
were missing for the Knee Society Score, five at baseline, 36 at one week, four at six 188 
weeks, three at 12 weeks and two at one year, the great majority because of research 189 
physiotherapist unavailability.  In one instance, a Knee Society Score was taken at one 190 
week, but other assessments were not taken because of patient illness. 191 
(b) Baseline characteristics 192 
 - 11 - 
 11
A randomization check showed no significant difference between age and sex of the two 193 
groups (Table 1).  Two-hundred and ten patients were retired, 17 were employed, three 194 
were house-wives, and one was seeking employment.  Three (2.6%) of the MP group, and 195 
six (5.2%) of the SV group had rheumatoid arthritis, the remainder had osteoarthritis.    196 
(c) Operative and Post-Operative Clinical  Characteristics  197 
Most patients had general anaesthesia, and 17/115 (14.8%) MP and 19/116 (16.4%) SV 198 
patients had epidural anaesthesia. The patella was replaced in 7/115 of the MP group 199 
(6.1%), and 10/116 (8.6%) of the SV group.  Ease of exposure was recorded in 228/231 200 
(98.7%) patients, with MP group mean 25.4 (SD 24.2) and SV group mean 32.8 (SD 201 
26.4), a statistically significant difference of 7.4 (95%CI, 0.8 to 14.0, p = 0.028), favouring 202 
the MP group.    A lateral release was performed in 14/115 (12.2%) of the MP group, and 203 
in  6/116 (5.2%) of the SV group.  The difference between these proportions, 7%, is not 204 
statistically significant (95% CI: -0.5% to 14.5%,  p=0.06). 205 
There were no differences between groups in the pain or analgesic diaries, in either the  206 
total scores over  seven days, or on an individual day basis.  The median length of stay was 207 
eight days,  with no difference between groups.  208 
(d) Longitudinal Outcomes 209 
Table 2 shows a cross-sectional summary of all mean outcome scores by group and time as 210 
an aid to interpretation of the formal longitudinal analyses. Table 3 shows a summary of 211 
the longitudinal outcomes, i.e. the between groups difference from baseline for each time 212 
period.   213 
(d.i) Knee Society Clinical Rating System 214 
 - 12 - 
 12
There was a great improvement in pain with time in both groups, and a small improvement 215 
in range of motion which was lower than baseline until between the six and 12 week 216 
follow-up (Table 2).  The functional score is lower than baseline at the one and six-week 217 
follow-ups.  The total score, functional score and knee score all show considerable benefit 218 
of surgery at the one year follow-up in both groups.  219 
At the one week follow-up, the SV group had a statistically significantly greater mean 220 
improvement in pain (5.7, Standard Error {SE} 2.74) and  knee score (6.8, SE 3.33) 221 
compared to baseline, and less deterioration in range of motion (7.4, SE 3.59), and total 222 
Knee Society Score (9.9, SE 4.44).  At six weeks the MP group had a non-statistically 223 
significant greater mean improvement in pain (4.8, SE 2.45) and knee score (5.5, SE 2.94). 224 
There were no significant differences at other time points.  These results support a modest, 225 
but clinically significant benefit for the SV group at one week post-operatively, with no 226 
significant difference at other time points.  A relative weakpoint of this measure compared 227 
to others, was 45 missing observations at the one week follow-up as the research 228 
physiotherapist was usually unavailable at one participating hospital during the early trial 229 
period. Further statistical analysis of this measure is presented in section (e). 230 
 231 
 (d.ii) WOMAC 232 
In both groups the global, function and pain scores showed major improvement with time 233 
and at the one year follow-up outcome scores were 15 to 30% of their baseline values. The 234 
largest absolute improvement in scores occurred within a week of surgery (Table 2). 235 
There were no statistically significant differences between groups at the one, six or 12 236 
week follow-ups, although the improvement in pain in the SV group at one week tended to 237 
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be better than the MP group (-1.2, SE 0.6).  At one year, the SV group had significantly 238 
greater improvement in pain (-1.6, SE 0.6), the SV group starting with an average pain 239 
score 0.7 units higher than the MP group and ending 0.8 units lower (tables 2 and 3).  The 240 
SV group also had a significantly lower global score (-5.2, SE 2.4) at one year, attributable 241 
to greater improvements in both pain and function (-3.2, SE 1.9). Further statistical 242 
analysis of this measure is presented in section (e). 243 
 244 
(d.iii) SF 36 245 
In both groups physical function and social function dipped at one week, then improved to 246 
one year.  Role-physical, and bodily pain showed continued improvement from one week 247 
to one year.  There was little change in other  measures. 248 
At one year, the SV group showed statistically significantly greater improvements in 249 
physical function (7.8, SE 3.1), and role-physical (13.7, SE 5.9), and tendency for greater 250 
improvement in pain (6.3, SE 4.1).  There were no significant differences in other 251 
outcomes, or at other time points.  The benefit in physical function for the SV group at one 252 
year was corroborated by non-parametric testing but not by the multiple logistic function. 253 
(d.iv)  EuroQol 254 
In both groups, there were improvements in pain, utility score and health status with time. 255 
At one week, the SV group improved statistically significantly more in the utility score 256 
(0.093, SE 0.04), and tended to have improved more in the pain score (-0.18, SE  0.09).  257 
At six and 12 weeks there were no significant differences. At one year, the SV group had 258 
improved significantly more as measured by the utility (0.091, SE 0.04), and pain scores (-259 
0.19, SE 0.09).   260 
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 262 
 263 
(e) Longitudinal Statistical Analysis 264 
Figures 1 and 2 show for the Knee Society Score and the global WOMAC score, 265 
respectively, the longitudinal trends based on the four differences from baseline outcome 266 
measurements for each group. In both figures, the large amount of variation at each 267 
examination, which is not unusual, should be noted.  The numbers in each group are 268 
approximately the same but, inevitably, the graphs show overprinting of symbols. The 269 
Knee Society results (Figure 1) show no average difference between groups over time, 270 
while the global WOMAC results show a small, persistent, benefit in favour of the SV 271 
group. 272 
The repeated measures data presented in Figures 1 and 2 were analysed by fitting a series 273 
of models which took selected baseline covariates (age, gender, smoking status, baseline 274 
KSS and baseline WOMAC), the time trend, the treatment by time interaction and the 275 
correlation between repeated measures on the same subject into account.  276 
In the case of the Knee Society data presented in Figure 1, in none of the models fitted was 277 
the treatment effect or the treatment by time interaction significant. In this analysis, we 278 
conclude that there is no significant difference in Knee Society Scores between the 279 
treatment groups studied.  280 
In relation to the WOMAC score, the results are different. The model (A) fitting the 281 
treatment indicator alone is not statistically significant (treatment regression coefficient 282 
b1=-2.59, SE 2.18). A similar finding emerges when model (B) containing the treatment 283 
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indicator and the (linear) time trend is fitted (b1=-2.65 , SE 2.19). However, when the 284 
baseline WOMAC score is added (model C), the treatment effect becomes significant (b1=-285 
2.4 , SE 1.17), and, when the treatment by time interaction is added (model D), it too is 286 
significant (b1=-2.44, se=1.19; interaction regression coefficient, b2 =-1.53. SE 0.67). 287 
Thus, when allowance is made for the baseline WOMAC score and time in the statistical 288 
model, a statistically significant difference emerges between the two groups. The SV 289 
procedure confers a greater reduction from baseline by approximately 2.5 WOMAC units 290 
of difference on average, and this benefit increases a little (but significantly) with time. 291 
These finding are broadly consistent with Figure 2 and Table 3. We noticed that the pain 292 
component of the Womac pain score differed significantly at one year between the groups. 293 
Pain was less in the SV group, the mean change from baseline to the 52 week examination 294 
was  -10.61 (se=0.41) Womac pain units and in the MP group it was -8.99 ( SE  0.37) 295 
units (t = 2.96, p=0.003).  296 
 297 
(f)  Adverse Events   298 
Overall, the number and type of adverse events recorded was similar between groups.  299 
Six deaths were recorded within one year of surgery.  One SV patient died the day after 300 
surgery from malignant hypertension during her general anaesthetic followed by an intra-301 
cerebral haemorrhage a few hours later.  Other deaths within one year of surgery appeared 302 
coincidental, with two SV deaths from cardiac failure, and three in the MP group from 303 
cancer, stroke, and an unknown cause.  304 
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Peri-operative adverse events were recorded in three MP patients, namely excessive 305 
bleeding, a dysplastic knee led to difficulties sizing a prosthesis, and an anterior femoral cut 306 
damaged the lateral aspect of the femur. 307 
In the SV group there was one joint infection, two deep incisional infections, three 308 
superficial incisional infections (one of whom was allocated the SV approach but received 309 
an MP approach), and two patients consulted their general medical practitioner  with 310 
wound problems but were not referred to a surgeon.    In the MP group there were three 311 
joint infections (one of whom had a revision joint arthroplasty), three superficial incisional 312 
infections, and seven patients consulted their general medical practitioner with wound 313 
problems. 314 
One SV patient had a partially retained wound drain, left in situ.   Two SV and three MP 315 
patients underwent knee manipulation for stiffness.    One MP patient had a patellar 316 
dislocation at six weeks, managed with manipulation and cast immobilisation. One MP 317 
patient at one year had had a positive bone scan for persisting pain, and was awaiting 318 
radiologist review. 319 
There was one pulmonary embolus in the SV group, and three in the MP group.  There 320 
was one confirmed and one possible but unconfirmed deep venous thrombosis, both in the 321 
SV group.  Two SV and one MP patients had a urinary tract infection at one week.  Two 322 
SV and one MP patients developed a chest infection at 1 week postoperatively.   One MP 323 
patient had a transient ischaemic attack at six weeks, and another atrial fibrillation.   324 
325 
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Discussion 326 
A novel finding of this study was that the group of patients who had their total knee 327 
arthroplasties’ through a sub-vastus approach had, one year after their operations, 328 
significantly less pain measured by the WOMAC and EuroQol questionnaires, and 329 
significantly better global WOMAC score, EuroQoL utility score, and physical function 330 
and role-physical scores measured by the SF36 questionnaire.  Sub-vastus patients also had 331 
significantly better scores one week post-operatively on the Knee Society overall, knee and 332 
pain scores, and range of motion.  On average, surgeons found that the medial parapatellar 333 
approach gave a greater ease of exposure.   Although other randomised studies comparing 334 
the two approaches have been reported, we believe that this investigation is the first to 335 
report follow-up at one year, and that the number of patients we recruited exceeds the 336 
combined total in the previous studies that we are aware of [3-6]. 337 
Care was taken to reduce bias by using minimization, by excluding participating surgeons 338 
from the collection of baseline and follow-up data and data analysis, and by blinding 339 
treatment allocation for both patients and the physiotherapists who took clinical 340 
measurements.  The groups were similar at baseline, follow-up completion was good apart 341 
from Knee Society Score at one week post-operatively, the analysis was based on intention 342 
to treat, and the participants themselves assessed their outcomes with the use of 343 
standardized questionnaire instruments up to one year post-operatively.   344 
The trial is relatively large for an orthopaedic trial.  However, the estimated differences are 345 
statistically imprecise, and this is an important limitation. There were wide confidence 346 
intervals, indicating that the true differences could have been larger or smaller than those 347 
reported. 348 
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The longitudinal modelling approach avoids many of the issues of multiple testing and 349 
gives an overall synthesis of the trial results. Although such analyses are available for all of 350 
the outcome variables studied, in the interests of space, the discussion is limited to the 351 
Knee Society Score and global WOMAC the variables in which there was particular prior 352 
interest among the research group.  In relation to the Knee Society Score, the main 353 
outcome variable in this study, these analyses conducted suggest  that there is no 354 
difference between the two treatment groups, and the position is neatly summarized in 355 
Figure 1 which supports the formal statistical analysis.  On the other hand, the findings in 356 
relation to the global WOMAC score show that the SV approach confers some benefit. In 357 
the SV group, Womac scores were statistically significantly lower (on average) by 2.5 358 
units of change. This finding only emerged after adjusting for baseline WOMAC score, 359 
time, and the treatment by time interaction. The inclusion of the baseline WOMAC score in 360 
the statistical model is key to the adjustment process, as this had the effect of 361 
approximately halving the standard error of the treatment effect. Naturally, the evidence 362 
would have been more persuasive had the benefit been demonstrable without the necessity 363 
for an adjusted analysis. However, such adjustments are routine in the modern analysis of 364 
longitudinal trials, and overall the evidence suggests a modest benefit (as indicated in 365 
Figure 2).  366 
An issue, at least to some extent, in all randomized controlled trials is their generalizability, 367 
as patients who are recruited differ from those who are not recruited, and it is then an issue 368 
of judgement of whether participants are sufficiently similar to patients treated by another 369 
clinician for the results to be generalized to that practice.  Most patients  at our hospital 370 
who were to receive a primary total knee arthroplasty were eligible for the trial, and only a 371 
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small proportion of eligible patients declined to participate.  All surgeons were experienced 372 
in total knee arthroplasty, although they had all employed the medial parapatellar approach 373 
as standard prior to the trial.  They therefore received additional training, supervised 374 
practice including video-analysis and feedback of their sub-vastus technique, prior to 375 
starting to recruit patients for the trial.  The hospital standard knee arthroplasty was used 376 
throughout the study. Formal statistical analysis of the outcome of total knee arthroplasty 377 
using either approach per each surgeon showed no difference, confirming that all surgeons 378 
were able to obtain an equally acceptable clinical outcome whichever approach they were 379 
required to use by the randomization process.  380 
The major criticisms of the sub-vastus approach have been poor and unpredicatable 381 
exposure, and difficulty with eversion of the patella [23,24], and our study did indicate that 382 
our surgeons found the ease of exposure less favourable with the sub-vastus approach.  383 
An early post-operative advantage of the sub-vastus approach observed in this study in the 384 
Knee Society Score measures, has also been reported in several small trials using a variety 385 
of outcome measures [3-6].  This has been explained by less disruption  of the extensor 386 
mechanism allowing better early rehabilitation [3-6].  The benefit of 70 greater range of 387 
motion for the SV group at one week post-operatively in this study, compares to a 230 388 
benefit for an SV group reported in one trial [5], no difference between approaches in 389 
patients undergoing bilateral knee arthroplasty [4], and earlier bending to 900 reported in 390 
another trial [6].  An early pain benefit reported in the KSS pain item one week post-391 
operatively is consistent with improved early pain reported elsewhere [6],  but we did not 392 
observe different use of analgesics [3,5].  Roysam [5], reported 17 days in hospital for the 393 
sub-vastus group compared to 21 days for the medial parapatellar group, whereas in our 394 
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study we found no difference, with the length of stay of about a week being standard 395 
hospital practice in our participating hospitals and more determined by policy than 396 
difference in rehabilitation.  397 
The medial parapatellar approach does give excellent exposure of the knee joint in total 398 
knee arthroplasty, and is used in most operations [7].  Problems with this approach, 399 
however, particularly patellar complications, have been reported in up to 50% of patients 400 
[12,25-29], and may be one reason why a significant minority of patients do not appear to 401 
derive substantial benefit from their total knee arthroplasties.  These problems motivated 402 
surgeons to search for other approaches, and Hofman [10] advocated the sub-vastus 403 
approach to avoid patellar complications through preservation of the extensor mechanism 404 
and less damage to the patella blood supply.   405 
At a practical level, surgeons involved in this study, who previously did not use the sub-406 
vastus approach, have introduced it as a frequently used option. Our study provides some 407 
evidence that, one year after a knee arthroplasty, patients who received a sub-vastus 408 
approach do better than those with a medial parapatellar approach.   In this study, both the 409 
one week and one year outcome were better in the sub-vastus group on some measures 410 
compared to the medial parapatellar group.  Longer term follow-up of patients in this 411 
study would allow identification of possible effects beyond the one year follow-up, and 412 
new trials in different settings with different surgeons and prostheses would be useful to 413 
see if our results are replicable in other settings. 414 
415 
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 497 
 498 
Table 1.  Comparison of Factors at Baseline 499 
 500 
Factors Sub-vastus Medial Parapatellar 
 
Categorical  n               % n                      % 
Sex  
      Male 
      Female 
 
60              (51.7)  
56              (48.3) 
 
 59                ( 51.3)  
 56                ( 48.7) 
Total                   116            (100   )        115               (100   )   
 
Continuous  Mean           SD Mean              SD 
Age  70.1           (8.0) 70.9               (8.1) 
 
NB: Comparison: Baseline check by multiple logistic 
function using 2 factors simultaneously - no evidence of 
imbalance. 
 
 
 - 27 - 
 27
Table 2a. Mean Values (SD) and numbers of patients for Longitudinal Outcomes for Medial ParaPatellar Group 501 
Time B B 1 1 6 6 12 12 52 52 
Variable N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
Knee Society            
Total   Score           (0-200) 111 80.1 (23.1)  96 62.7 (25.3) 107 98.5 (28.9) 107 111.1(34.2) 107 125.8(31.1) 
Function Score       (0-100) 111 38.8 (16.6)  98 18.4 (12.6) 107 31.4 (18.7) 107   42.1(22.0) 108  50.6 (21.0) 
Knee Score             (0-100) 111 41.3 (13.9)  96 44.5 (18.1) 107 67.0 (18.4) 107  69.0 (19.8) 107  75.2 (17.6) 
Range of Motion      (0) 111 89.3 (21.9)  98 57.2 (17.4) 107 81.8 (17.2) 107  86.3 (19.6) 108  94.9 (15.5) 
Pain                         (0- 50) 111   9.6 (10.2)  96 19.2 (15.6) 107 36.2 (15.0) 107  36.4 (16.5) 108  39.4 (15.7) 
WOMAC           
Global                      (0-96) 115 44.5 (16.2) 112 20.3 (14.7) 108 11.3 (9.9) 107 11.9 (12.8) 111 11.5 (14.5) 
Function                   (0-64) 115 28.5 (13.3) 112 10.2 (11.8) 108   5.7 (6.9) 109   7.2  (10.2) 111   7.3 (10.1) 
Pain                          (0-20) 115 11.6 (  3.3) 112   6.3 (  3.9) 108   3.4 (3.5) 107   2.5  (  3.1) 111   2.5 (  3.9) 
Stiffness                    (0- 8) 115   4.4  ( 2.2) 112   3.9 (  2.0) 108   2.4 (1.8) 109   2.2  (  1.8) 111   1.7 (  1.9) 
SF 36           
Physical Function 115 20.6 (20.0) 113 10.0 (14.7) 108 37.8 (23.4) 109 53.0 (26.2) 111 59.3 (25.6) 
Role - Physical 115   4.2 (17.2) 112 29.2 (36.1) 108 53.0 (44.4) 109 61.2 (44.8) 111 67.1 (43.6) 
Bodily Pain 115 37.8 (24.3) 112 52.0 (28.9) 108 75.2 (27.5) 109 74.8 (28.0) 111 78.7 (28.2) 
Health Perception 115 73.5 (20.0) 113 77.1 (19.2) 108 81.2 (14.8) 109 79.4 (19.2) 111 74.2 (23.6) 
Energy 115 44.1 (17.7) 112 42.8 (17.9) 108 49.4 (15.8) 109 54.4 (15.6) 111 52.4 (15.9) 
Social Function 115 74.8 (38.4) 112 25.0 (34.2) 108 68.2 (41.2) 109 84.7 (31.1) 111 91.7 (20.7) 
Role - Mental 115 94.2 (23.1) 112 89.0 (31.1) 108 96.3 (19.0) 109 92.0 (26.8) 111 98.2 (13.4) 
Mental Health 115 77.3 (15.0) 112 79.0 (14.9) 108 79.0 (15.7) 109 76.8 (14.5) 111 75.9 (14.5) 
EuroQol           
Health status                 (0-100) 115 73.4 (15.9) 113 72.0 (17.5) 108 79.8 (13.5) 109 79.1 (16.2) 111 79.6 (17.1) 
Utility score                (0-   1) 115 0.29 (0.27) 113 0.35 (0.19) 107 0.58 (0.24) 109 0.73 (0.29) 111 0.80 (0.26) 
Pain                               (0-   2) 115 1.48 (0.52) 113 1.06 (0.50) 107 0.61 (0.54) 109 0.55 (0.60) 111 0.46 (0.57) 
 502 
 503 
 504 
505 
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Table 2b Mean Values (SD) and numbers of patients for Longitudinal Outcomes for Sub-Vastus Group 506 
Time B B 1 1 6 6 12 12 52 52 
Variable N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
Knee Society            
Total   Score           (0-200) 115 80.2 (25.3) 91 71.0 (26.0) 108 95.6 (27.7) 108 111.0(31.5) 111 129.1(31.0) 
Function Score       (0-100) 115 37.4 (16.4) 91 19.7 (13.1) 108 32.7 (17.3) 108  42.8 (21.1) 111  52.3 (24.5) 
Knee Score             (0-100) 115 42.8 (16.3) 91 51.3 (20.4) 108 62.8 (20.4) 108  68.1(18.9) 111  76.8 (15.8) 
Range of Motion      (0) 115 87.0 (23.5) 91 61.2 (15.3) 108 80.8 (14.1) 108  87.1(17.7) 112  96.1 (14.9) 
Pain                         (0- 50) 115 10.8 (11.5) 92 25.4 (17.9) 108 32.0 (17.8) 108  35.6(16.1) 111  41.1 (15.0) 
WOMAC           
Global                      (0-96) 116 44.7 (17.5) 112 18.3 (13.9) 110 12.2 (12.2) 108 9.0 (9.3) 111    6.4 (9.7) 
Function                   (0-64) 116 28.1 (13.7) 112   8.9 (11.4) 110   6.2 ( 8.9) 109 4.7 (7.0) 112    3.7 (6.7) 
Pain                          (0-20) 116 12.3 (  3.6) 112   6.0  ( 3.8) 110   3.8 ( 4.2) 108 2.4 (3.1) 111    1.7 (3.0) 
Stiffness                   (0-  8) 116   4.4 (  2.8) 112   3.3  ( 1.9) 110   2.2 ( 1.7) 109 2.0 (1.7) 113    1.1 (1.4) 
SF 36           
Physical Function 116 20.8 (17.8) 112 11.7 (13.0) 110 39.6 (22.2) 110 56.5 (27.2) 113  67.3 (22.3) 
Role - Physical 116   6.7 (23.6) 112 26.3 (29.6) 110 55.0 (44.4) 110 68.0 (42.3) 113  83.4 (36.5) 
Bodily Pain 116 39.3 (23.1) 112 54.9 (27.8) 110 75.1 (27.2) 110 78.9 (27.0) 113  86.2 (24.2) 
Health Perception 116 74.3 (21.8) 112 73.8 (20.7) 110 78.4 (19.4) 110 79.1 (18.6) 113  74.6 (21.4) 
Energy 116 45.3 (17.6) 112 44.6 (17.6) 110 50.3 (18.3) 110 52.9 (18.5) 113  55.7 (15.7) 
Social Function 116 73.6 (40.8) 112 35.7 (42.8) 110 67.1 (40.4) 110 87.8 (28.0) 113  94.2 (19.1) 
Role - Mental 116 95.7 (20.4) 112 92.9 (25.1) 110 96.4 (18.8) 110 98.8 (10.0) 113  98.5 (11.3) 
Mental Health 116 77.8 (14.4) 112 82.4 (11.8) 110 77.4 (14.8) 110 79.6 (12.8) 113  78.0 (12.3) 
EuroQol           
Health status                 (0-100) 116 72.7 (16.6) 112 72.4 (16.9) 110 78.4 (16.8) 110 81.8 (13.4) 113  81.4 (16.3) 
Utility score               (0-   1) 116 0.27 (0.27) 112 0.42 (0.19) 110 0.61 (0.26) 110 0.77 (0.24) 113  0.87  (0.21) 
Pain                               (0-   2) 116 1.52 (0.52) 112 0.93 (0.80) 110 0.72 (0.54) 110 0.54 (0.52) 113  0.31  (0.48) 
 507 
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Table 3.  Differences in group averages (Sub-vastus group – Medial Parapatellar group) of change from baseline (follow-up  – baseline), (95% CI, 509 
and p values from independent t test).  Positive differences favour the sub-vastus group, except for all WOMAC and the EuroQol pain scores 510 
where negative differences favour the sub-vastus group. 511 
 512 
Variable One Week 6 Weeks 12 Weeks 52wks 
 Difference 95%CI p Differenc 95%CI p Difference 95%CI p Differenc 95%CI p 
Knee Society Score (KSS) 
Total Score  9.87   1.12 18.63 0.027  -2.84 -  4.80 10.50  0.46  -1.15 -9.72   7.42 0.79   1.92 -5.90   9.75 0.63 
Function Sco’  3.30 - 1.43   8.03 0.17   2.64 -  7.24   1.96  0.26   1.17 -3.43   5.77 0.62   1.30 -4.10   6.70 0.64 
Knee Score  6.78   0.20 13.36 0.043 - 5.49 -11.29   0.32  0.064  -2.32 -8.51   3.87 0.46   0.65 -4.63   5.93 0.81 
ROM  (0)  7.44   0.37 14.53 0.039  -0.22 -  6.71   6.26  0.95   3.79 -3.36 10.95 0.30   4.87 -1.11 10.85 0.11 
Pain  5.70   0.31 11.10 0.038  -4.75 -  9.59   0.08  0.054  -1.94 -6.82   2.94 0.43   0.68 -5.07   3.72 0.76 
WOMAC 
Global (0-96) -2.21   2.96  -7.39 0.40   0.37    5.09  -4.35   0.88  -3.20   1.72  -8.12 0.20  -5.20 -0.49  -9.90 0.031 
Functi’ (0-64) -0.52   3.67  -4.71 0.81   0.99    4.71  -2.72 0.60  -2.54   1.46  -6.54 0.21  -3.15  0.55  -6.84 0.095 
Pain     (0-20) -1.17   0.08  -2.42 0.066  -0.57    0.70   -1.84 0.38  -0.93   0.31  -2.16 0.14  -1.62 -2.70  -0.55 0.003 
Stiffness (0-8) -0.53   0.24  -1.30 0.18  -0.05    0.68  -0.79 0.89  -0.24   0.49  -0.97 0.52  -0.56  0.16  -1.29 0.13 
SF 36 
Physical Func’   1.65 -  3.94   7.23 0.56  1.97 -  4.39   8.33 0.54  3.43 -3.67 10.53 0.34   7.81  1.64 13.97 0.013 
Role-Physical - 5.58 -15.36   4.19 0.26 -0.66 -14.19 12.88 0.92  3.11 -9.40 15.63 0.62 13.71  2.13 25.29 0.020 
Bodily Pain   1.69 -  6.91 10.29 0.70 -1.42 -10.12   7.26 0.75  2.84 -6.18 11.87 0.54   6.30 -1.71 14.31 0.12 
Health Percep’ - 3.66 -  7.98   0.65 0.10 -2.12 -  6.86   2.61 0.38 -0.75 -5.38   3.89 0.75  -0.37 -5.94   5.19 0.90 
Energy   0.71 -  4.78   6.20 0.80 -0.19 -  5.31   4.92 0.94 -1.68 -6.71   3.34 0.51   2.50 -1.99   7.00 0.27 
Social Functi’ 12.20 -  1.42 25.82 0.79  0.84 -14.10 15.79 0.91  5.06 -7.33 17.44 0.42   5.02 -5.50 15.87 0.36 
Role - Mental   2.38 -  5.58 10.34 0.56 -1.56 -  9.56   6.44 0.70  5.17 -2.82 13.15 0.20  -1.25 -8.01   5.50 0.72 
Mental Health   3.61 -  0.31   7.52 0.071 -1.30 -  5.88   3.29 0.58  1.85 -2.51   6.22 0.40   1.55 -2.98   6.07 0.50 
EuroQol 
Health Status   1.15  - 3.95 6.25 0.66 0.23 -2.54   5.25 0.93  4.21 -2.54  9.22 0.10    3.39 -2.76  8.83 0.22 
Utility Score   0.093  0.016 0.171 0.018  0.055 -0.035   0.145 0.23  0.068 -0.024  0.160 0.15    0.091  0.009  0.172 0.029 
Pain  -0.18    0.00 -0.36 0.051 0.06 0.25   -0.13 0.53  -0.06   0.14 -0.25 0.58   -0.19 -0.01 -0.36 0.040 
 513 
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 515 
  516 
Figure 1: Total Knee Society Score by Time for each group:  517 
Diamonds = SV, Circles = MP; trend lines show average  518 
Evolution (solid line=SV, broken line=MP) 519 
 520 
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 521 
Figure 2: Total Womac Score by Time for each group:  522 
Diamonds = SV, Circles = MP; trend lines show average  523 
Evolution (solid line=SV, broken line=MP) 524 
